# COMPARISON SOFTWARE TO ASSESS NGS ACCURACY & BOOST TRANSLATIONAL RESEARCH

> **NIH NIH R43** · SOLVE, INC. · 2020 · $251,664

## Abstract

Project Summary
SolveBio is a cloud-based data platform for biopharma clinical and translational research. The
goal of this project is to implement a graphical user interface-based comparison software suite
to flexibly compare next generation sequencing (NGS) results for patients across replicates,
assays, commercial vendors, biospecimens, and timepoints, with an initial application in
assessing liquid biopsy accuracy. Liquid biopsy is an emerging non-invasive method for
screening and monitoring actionable mutations but technological and biological hurdles remain.
Comparing and evaluating NGS data generated by different assays is difficult to impossible for
most individual scientists. Solving this challenge has the potential to catalyze progress in the
adoption of precision oncology and facilitate the broader application of next-generation
sequencing technologies to provide more efficient clinical care to patients.

## Key facts

- **NIH application ID:** 10081512
- **Project number:** 1R43TR003499-01
- **Recipient organization:** SOLVE, INC.
- **Principal Investigator:** Xing Xu
- **Activity code:** R43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $251,664
- **Award type:** 1
- **Project period:** 2020-07-01 → 2021-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10081512

## Citation

> US National Institutes of Health, RePORTER application 10081512, COMPARISON SOFTWARE TO ASSESS NGS ACCURACY & BOOST TRANSLATIONAL RESEARCH (1R43TR003499-01). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10081512. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*